Novavax

YTD

ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines.

CEO

John C.s Jacobs

CEOJohn C.s Jacobs

Employees

952

Employees952

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1987

Founded1987

Employees

952

Employees952

NVAX Key Statistics

Market cap

1.44B

Market cap1.44B

Price-Earnings ratio

3.82

Price-Earnings ratio3.82

Dividend yield

—

Dividend yield—

Average volume

5.07M

Average volume5.07M

High today

$9.04

High today$9.04

Low today

$8.46

Low today$8.46

Open price

$8.68

Open price$8.68

Volume

5.50M

Volume5.50M

52 Week high

$12.86

52 Week high$12.86

52 Week low

$5.01

52 Week low$5.01

NVAX News

Benzinga 14h

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19...

TipRanks 17h

Shah Capital pushes for Novavax’s sale on underperformance, Reuters says

Shah Capital has urged Novavax’s (NVAX) board to pursue a sale of the biotech, citing a third consecutive year of poor roll-out of its COVID-19 shot, the hedge...

Simply Wall St 21h

Novavax Valuation in Focus After Sanofi Deal Unlocks Milestone Payments and Royalty Potential

Novavax (NVAX) has just completed the transfer of marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi in the European Union. This move unlock...

Analyst ratings

57%

of 7 ratings

Buy

57.1%

Hold

14.3%

Sell

28.6%

More NVAX News

Simply Wall St 4d

Novavax Is Down 11.9% After Sanofi Takes Over EU Marketing of Nuvaxovid Vaccine

Sanofi announced it has completed the transfer of European Union marketing authorization for Novavax's COVID-19 vaccine, Nuvaxovid, taking on full commercial an...

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.